Venous thromboembolic events
It exists, but it is low and increases with age in all women, whether or not they use a combined oral contraceptive (COC). It is more important on contraceptives to 3rd or 4th generation only under 1st or 2nd generation COCs.
Between 2000 and 2011, the risk of venous thromboembolism associated with COCs is estimated at 2,529 per year, of which 1,751 are attributable to the 3rd and 4th generation pills.
Premature deaths
The annual number of deaths from pulmonary embolism associated with the use of COCs is estimated at 20, including 6 deaths attributable to 1st and 2nd generation COCs and 14 to 3rd and 4th generation COCs.
To reduce the risk of venous thromboembolic events and associated death, various practices should be considered:
• second-line use of 3rd and 4th generation COCs,
• consideration of risk factors before any prescription,
• raising awareness among women and healthcare professionals of the risk of venous thromboembolic events and the associated signs that should alert them and lead them to consult for early treatment,
• use of the contraceptive method best suited to each user.
Women and contraception
The decline in the use of 3rd and 4th generation pills has continued since the start of the year. This trend is particularly remarkable for 3rd and 4th generation COCs since the observed decrease reaches the level of 34%. This decrease is accompanied by a significant increase in the prescription of 2nd generation COCs, which for its part increased by 26.5% in February 2013 compared to February 2012.
These data confirm that doctors have modified their prescriptions in line with the recommendations sent at the end of December by the ANSM to prescribers.
The pill is not the only method of contraception. It is essential that each patient, with her doctor, find the method that best suits her lifestyle and her potential medical risks.
